Effect of different statins on glycometabolism in patients with non-diabetic coronary atherosclerotic heart disease
Liu Sining
Tian Xuefeng
Wang Zheng
Xu Meng
Abstract：Objective To investigate the effect of different statins on glycometabolism in patients with non-diabetic coronary atherosclerotic heart disease(CHD).Methods Clinical data of patients with non-diabetic CHD admitted to Heilongjiang Provincial Hospital from January 2013 to June 2017 were retrospectively analyzed.The patients were divided into atorvastatin group(20 mg/d),rosuvastatin group(10 mg/d) and pitavastatin group (2 mg/d),with 60 cases in each group.Changes of blood lipids and glycometabolism indexes were analyzed before,4 and 12 weeks after treatment.Results Levels of serum triglyceride,total cholesterol and low density lipoprotein cholesterol in the three group significantly decreased and high density lipoprotein cholesterol level significantly increased 4 and 12 weeks after treatment (all P ＜ 0.05);there was no significant difference among the three groups(P ＞ 0.05).After 12 weeks of treatment,serum levels of fasting blood glucose and glycosylated hemoglobin significantly increased and fasting insulin significantly decreased compared to those before treatment in the atorvastatin group and rosuvastatin group [atorvastatin group:(5.9 ± 0.9) mmol/L vs (5.4 ± 0.9) mmol/L,(6.7 ± 0.8) ％ vs (6.4 ± 0.5) ％,(8.1 ± 0.8) mIU/L vs (8.6 ± 0.9) mIU/L;rosuvastatin group:(5.8 ±0.9)mmol/L vs (5.4 ± 1.0)mmol/L,(6.7 ±0.8)％ vs (6.4 ±0.9)％,(8.1 ±0.8)mIU/L vs (8.2 ±0.8) mIU/L] (all P ＜ 0.05).Conclusion Pitavastatin shows no obvious effect on glycometabolism in patients with non-diabetic CHD and does not increase the risk of newly onset diabetes in patients with CHD.
Keywords：Coronary atherosclerotic heart diseaseAtorvastatinRosuvastatinPitavastatinGlycometabolism
Publication Date：2019-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 192-195 )